Russia licenses second vaccine

RUSSIA / FSU POLITICS - In Brief 15 Oct 2020 by Alex Teddy
On October 14 the announcement was made by the president. The fact that Putin said it indicates the importance attached thereto. The peptide-based shot was created by Vektor (State Virology and Biotechnology Center). The EpiVacCorona has been administered to some cabinet ministers. Over 100 volunteers have already had it trialed on them. A new trial with over 40,000 volunteers shall commence. Sixty thousand doses will be manufactured asap, so that if the new trial is successful, the drug can be administered to patients immediately. The Ministry of Health has not provided particulars about the trial outcomes or the approval procedure. The ministry said it is being examined for safety. That does not inspire confidence! If it is still being scrutinized, then why is it being rolled out to such a big trial sample?Vektor is an erstwhile bioweapons lab. It is one of the only two places in the world with samples of smallpox. The government said a third type of coronavirus vaccine will be licensed in December 2020. A vaccine is badly needed. The country has had 1.3 million cases of coronavirus but a low death rate from those cases. Infections are spreading very rapidly. Russia is the 4th most affected country. There are some local semi-lockdowns. A national total lockdown does not seem to have been even contemplated.

Now read on...

Register to sample a report

Register
Sign-in
Forgot your password?
Copyright 2024 GlobalSource Partners. All rights reserved. This is prepared for GlobalSource Partners’ clients and may not be redistributed, reproduced, stored in a retrieval system, retransmitted or disclosed, in whole or in part, or in any form or manner, without the express written consent of GlobalSource Partners. This is distributed simultaneously to our website and other portals used by GlobalSource Partners. The information herein was obtained from various sources and is believed to be reliable but GlobalSource Partners does not warrant its completeness or accuracy. Neither GlobalSource Partners nor any Country Analyst, officer or employee accepts any liability whatsoever for any direct, indirect or consequential damages or losses rising from any use of this or its contents.